NCT00392496View on ClinicalTrials.gov

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaStage IV Adult Diffuse Large Cell Lymphoma
Interventions
DRUG

sunitinib malate

Given orally

Trial Locations (1)

K7L 3N6

National Cancer Institute of Canada Clinical Trials Group, Kingston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00392496 - Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter